A Phase 3 interventional study of Asundexian (BAY2433334) and Apixaban in Prevention of Stroke or Systemic Embolism and Atrial Fibrillation, sponsored by Bayer. Terminated at 1,069 sites in 38 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-09.
Sponsored by Bayer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies in Atrial Fibrillation by Bayer — 1 open to participants now, 1 under way, none of them phase 3. Atrial Fibrillation · Bayer.
Among the 64 studies in Atrial Fibrillation by Bayer, this one has the largest enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2022, is one of 4 in phase 3, and was the 63rd registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →1 of the 64 studies in Atrial Fibrillation by Bayer is open now, in 8 countries. Recruiting first, the newest first:
Bayer · Sites in United States, Belgium, Bulgaria and 5 more countries
Ages 18–85
By country, each count listing its studies:
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 3 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 14,830 is above the median of 150 across 2,480 interventional studies indexed under Atrial Fibrillation.
Median enrollment 100 across the 13 interventional studies, 3,055 across the 51 observational. Of the 61 that completed or were terminated, 4 (7%) have results posted.
This tab as a report to print or save as PDF → With an account.
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 133 (62%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 64 studies in Atrial Fibrillation by Bayer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Researchers are looking for a better way to treat people with atrial fibrillation (AF) and prevent stroke or systemic embolism (blood clots travelling through the blood stream to plug another vessel).
Atrial fibrillation is a condition of having irregular and often rapid heartbeat. It can lead to the formation of blood clots in the heart which can travel through the blood stream to plug another vessel, and like this lead to serious and life-threatening conditions, such as a stroke. A stroke occurs because the brain tissue beyond the blockage no longer receives nutrients and oxygen so that brain cells die. As strokes arising from atrial fibrillation can involve extensive areas of the brain, it is important to prevent them.
Blood clots are formed in a process known as coagulation. Medications are already available to prevent the formation of blood clots. When taken by mouth (orally), they are known as oral anticoagulants (OACs) including apixaban. OACs decrease the risk of the above-mentioned serious and life-threatening conditions. The main side effect of OACs is an increase of the risk of bleeding.
The study treatment asundexian is a new type of anticoagulant currently under development to provide further treatment options. Asundexian aims to further improve the standard of care with regard to the risk of bleeding.
The main purpose of this study is to collect more data about how well asundexian works to prevent stroke and systemic embolism and how safe it is compared to apixaban in people with atrial fibrillation and at high risk for stroke.
To see how well the study treatment asundexian works researchers compare:
To see how safe asundexian is, the researchers will compare how often major bleedings occur after taking the study treatments asundexian and apixaban, respectively. Major bleedings are bleedings that have a serious or even life-threatening impact on a person's health.
The study participants will be randomly (by chance) assigned to 1 of 2 treatment groups, A and B. Dependent on the treatment group, the participants will either take the study treatment asundexian by mouth once a day or apixaban by mouth twice a day for approximately 9 - 33 months.
Each participant will be in the study for approximately 9 - 34 months. There will be visits to the study site every 3 to 6 months and up to 7 phone calls. Those participants who do not want or are unable to have visits to the study site may join the study remotely in selected locations. The location name contains the abbreviation - DCT in such cases.
During the study, the study team will:
An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if they do not think the adverse events might be related to the study treatments.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
CHA2DS2-VASc score ≥ 3 if male or ≥ 4 if female, OR CHA2DS2-VASc score of 2 if male or 3 if female and at least one of the following enrichment criteria:
Exclusion Criteria:
Concomitant use of or anticipated need for:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive asundexian and apixaban matching placebo.
Drug: Asundexian (BAY2433334) · Drug: Apixaban matching placebo
Participants will receive apixaban and asundexian matching placebo.
Drug: Apixaban · Drug: Asundexian matching placebo
Once a day
5 mg or 2.5 mg, twice a day, according to product label.
Placebo to asundexian, once a day
Placebo to apixaban, twice a day
Number of Participants With Composite of Stroke or Systemic Embolism
The assessment was based on the cause-specific hazard ratio (csHR), comparing asundexian with apixaban which is based on time to first event. Stroke was defined as an acute episode of focal or global neurological dysfunction caused by an injury of the brain, spinal cord, or retina as a result of hemorrhage or infarction. Systemic embolism is defined as abrupt vascular insufficiency associated with clinical or radiological evidence of arterial occlusion in the absence of other likely mechanisms (this does not include myocardial infarction, thromboembolism of the pulmonary vasculature or venous thrombosis, e.g. pulmonary embolism or deep venous thrombosis).
Time frame: Approximately 12 months
Number of Participants With International Society on Thrombosis and Hemostasis (ISTH) Major Bleeding
Assessment based on the (csHR), comparing asundexian with apixaban which is based on time to first event. ISTH Major Bleeding was defined as an event that meets at least one of the below criteria, based on the definition given by the ISTH (Schulman and Kearon 2005): * Fatal bleeding, and/or * Symptomatic bleeding in a critical area or organ (intracranial, intraspinal, intraocular with compromised vision, pericardial, retroperitoneal, intra-articular, or intramuscular with compartment syndrome), and/or * Clinically overt\* bleeding associated with a recent (within 48 hours) decrease in the hemoglobin level of ≥ 2 g/dL (20 g/L; 1.24 mmol/L) compared with the most recent hemoglobin value available before the event, and/or * Clinically overt\* bleeding leading to transfusion of 2 or more units of packed red blood cells or whole blood. * Overt bleeding required the identification of the bleeding location and the hemoglobin drop and/or transfusion needed to be related to the bleeding.
Time frame: Approximately 12 months
Number of Participants With Composite of Stroke, Systemic Embolism, or ISTH Major Bleeding
The assessment was based on the cause-specific hazard ratio (csHR), comparing asundexian with apixaban which is based on time to first event.
Time frame: Approximately 12 months
Number of Participants With Composite of Ischemic Stroke or Systemic Embolism
The assessment was based on the cause-specific hazard ratio (csHR), comparing asundexian with apixaban which is based on time to first event. An ischemic stroke was defined as the rapid onset (or present on awakening) of a new focal neurological deficit with clinical (\> 24 hours symptoms / signs) or imaging evidence of infarction that is not attributable to a non-ischemic cause (i.e. not associated with infection, tumor, seizure, severe metabolic disease).
Time frame: Approximately 12 months
Number of Participants With All-cause Mortality
The assessment was based on the cause-specific hazard ratio (csHR), comparing asundexian with apixaban which is based on time to first event.
Time frame: Approximately 12 months
Number of Participants With Ischemic Stroke
The assessment was based on the cause-specific hazard ratio (csHR), comparing asundexian with apixaban which is based on time to first event. An ischemic stroke was defined as the rapid onset (or present on awakening) of a new focal neurological deficit with clinical (\> 24 hours symptoms / signs) or imaging evidence of infarction that is not attributable to a non-ischemic cause (i.e. not associated with infection, tumor, seizure, severe metabolic disease).
Time frame: Approximately 12 months
Number of Participants With Cardiovascular (CV) Death
The assessment was based on the cause-specific hazard ratio (csHR), comparing asundexian with apixaban which is based on time to first event. CV death included death due to stroke, myocardial infarction, heart failure or cardiogenic shock, sudden death or any other death due to other cardiovascular causes or CV procedures. In addition, death due to non-traumatic cardiovascular hemorrhage will be included, e.g. non-stroke intracranial hemorrhage, non-procedural or non-traumatic vascular rupture (e.g. aortic aneurysm), or hemorrhage causing cardiac tamponade
Time frame: Approximately 12 months
Number of Participants With Composite of CV Death, Stroke, or Myocardial Infarction (MI)
The assessment was based on the cause-specific hazard ratio (csHR), comparing asundexian with apixaban which is based on time to first event. The diagnosis of MI requires the combination of: * Presence of acute myocardial injury (changes in cardiac biomarkers) and * Evidence of acute myocardial ischemia derived from the clinical presentation, electrocardiographic changes, or the results of myocardial or coronary artery imaging, or in case of post mortem pathological findings irrespective of biomarker values.
Time frame: Approximately 12 months
Number of Participants With Composite of ISTH Major or Clinically Relevant Non-major Bleeding
The assessment was based on the cause-specific hazard ratio (csHR), comparing asundexian with apixaban which is based on time to first event. Clinically relevant non-major bleeding was considered any sign or symptom of acute or sub-acute clinically overt bleeding that does not fit the criteria for the ISTH definition of major bleeding, but does meet at least one of the following criteria (based on criteria published by the EMA) (EMA 2014): * requiring medical or surgical treatment by a healthcare professional for bleeding * leading to hospitalization or increased level of care for bleeding * a change in antithrombotic therapy (including study intervention) for bleeding \*Overt bleeding required the identification of the bleeding location.
Time frame: Approximately 12 months
Number of Participants With Clinically Relevant Non-major Bleeding
The assessment was based on the cause-specific hazard ratio (csHR), comparing asundexian with apixaban which is based on time to first event.
Time frame: Approximately 12 months
Number of Participants With Hemorrhagic Stroke
The assessment was based on the cause-specific hazard ratio (csHR), comparing asundexian with apixaban which is based on time to first event. Hemorrhagic stroke was defined as an acute, atraumatic extravasation of blood into the brain parenchyma, intraventricular or subarachnoid space with associated neurological symptoms. This does not include microbleeds or hemorrhagic transformation of an ischemic stroke.
Time frame: Approximately 12 months
Number of Participants With Intracranial Hemorrhage
The assessment was based on the cause-specific hazard ratio (csHR), comparing asundexian with apixaban which is based on time to first event.
Time frame: Approximately 12 months
Number of Participants With Fatal Bleeding
The assessment was based on the cause-specific hazard ratio (csHR), comparing asundexian with apixaban which is based on time to first event.
Time frame: Approximately 12 months
Number of Participants With Minor Bleeding
The assessment was based on the cause-specific hazard ratio (csHR), comparing asundexian with apixaban which is based on time to first event. All other overt bleeding episodes not meeting the criteria for ISTH major or clinically relevant non-major bleeding were classified as minor bleeding (for example, bleeding from a minor wound that does not prompt a treatment for the bleeding, for instance with surgical hemostasis, or epistaxis that does not require a medical treatment for bleeding or a change in antithrombotic therapy).
Time frame: Approximately 12 months
Number of Participants With Composite of Stroke, Systemic Embolism, ISTH Major Bleeding, or All-cause Mortality
The assessment was based on the cause-specific hazard ratio (csHR), comparing asundexian with apixaban which is based on time to first event.
Time frame: Approximately 12 months
Number of Participants With Composite of Disabling Stroke (mRS ≥ 3), Critical Bleeding, or All-cause Mortality
The assessment was based on the cause-specific hazard ratio (csHR), comparing asundexian with apixaban which is based on time to first event. Critical bleeding was defined as symptomatic bleeding in either of the following critical locations (intracranial, intraspinal, pericardial, intra-articular, or retroperitoneal) or as intraocular bleeding with compromised vision or intramuscular bleeding with compartment syndrome.
Time frame: Approximately 12 months
Study was conducted at 1035 study centers across in Asia, Europe, North America, South America, and Australia, between 05-Dec-2022 (first participant first visit) and 31-Jan-2024 (last participant last visit).
| Milestone | Asundexian | Apixaban |
|---|---|---|
| Started | 7383 | 7374 |
| Completed | 6901 | 7012 |
| Not completed | 482 | 362 |
| Withdrew: Adverse event | 117 | 90 |
| Withdrew: Death | 53 | 57 |
| Withdrew: Lost to follow-up | 6 | 3 |
| Withdrew: Other | 18 | 15 |
| Withdrew: Outcome event | 64 | 36 |
| Withdrew: Physician decision | 33 | 19 |
| Withdrew: Protocol-specified withdrawal criterion met | 2 | 2 |
| Withdrew: Site terminated by sponsor | 10 | 10 |
| Withdrew: Study terminated by sponsor | 1 | 0 |
| Withdrew: Withdrawal by subject | 178 | 130 |
The assessment was based on the cause-specific hazard ratio (csHR), comparing asundexian with apixaban which is based on time to first event. Stroke was defined as an acute episode of focal or global neurological dysfunction caused by an injury of the brain, spinal cord, or retina as a result of hemorrhage or infarction. Systemic embolism is defined as abrupt vascular insufficiency associated with clinical or radiological evidence of arterial occlusion in the absence of other likely mechanisms (this does not include myocardial infarction, thromboembolism of the pulmonary vasculature or venous thrombosis, e.g. pulmonary embolism or deep venous thrombosis).
| Participants | Asundexian | Apixaban |
|---|---|---|
| Number of Participants With Composite of Stroke or Systemic Embolism | 98 | 26 |
Assessment based on the (csHR), comparing asundexian with apixaban which is based on time to first event. ISTH Major Bleeding was defined as an event that meets at least one of the below criteria, based on the definition given by the ISTH (Schulman and Kearon 2005): * Fatal bleeding, and/or * Symptomatic bleeding in a critical area or organ (intracranial, intraspinal, intraocular with compromised vision, pericardial, retroperitoneal, intra-articular, or intramuscular with compartment syndrome), and/or * Clinically overt\* bleeding associated with a recent (within 48 hours) decrease in the hemoglobin level of ≥ 2 g/dL (20 g/L; 1.24 mmol/L) compared with the most recent hemoglobin value available before the event, and/or * Clinically overt\* bleeding leading to transfusion of 2 or more units of packed red blood cells or whole blood. * Overt bleeding required the identification of the bleeding location and the hemoglobin drop and/or transfusion needed to be related to the bleeding.
| Participants | Asundexian | Apixaban |
|---|---|---|
| Number of Participants With International Society on Thrombosis and Hemostasis (ISTH) Major Bleeding | 17 | 53 |
The assessment was based on the cause-specific hazard ratio (csHR), comparing asundexian with apixaban which is based on time to first event.
| Participants | Asundexian | Apixaban |
|---|---|---|
| Number of Participants With Composite of Stroke, Systemic Embolism, or ISTH Major Bleeding | 120 | 75 |
The assessment was based on the cause-specific hazard ratio (csHR), comparing asundexian with apixaban which is based on time to first event. An ischemic stroke was defined as the rapid onset (or present on awakening) of a new focal neurological deficit with clinical (\> 24 hours symptoms / signs) or imaging evidence of infarction that is not attributable to a non-ischemic cause (i.e. not associated with infection, tumor, seizure, severe metabolic disease).
| Participants | Asundexian | Apixaban |
|---|---|---|
| Number of Participants With Composite of Ischemic Stroke or Systemic Embolism | 96 | 22 |
The assessment was based on the cause-specific hazard ratio (csHR), comparing asundexian with apixaban which is based on time to first event.
| Participants | Asundexian | Apixaban |
|---|---|---|
| Number of Participants With All-cause Mortality | 60 | 71 |
The assessment was based on the cause-specific hazard ratio (csHR), comparing asundexian with apixaban which is based on time to first event. An ischemic stroke was defined as the rapid onset (or present on awakening) of a new focal neurological deficit with clinical (\> 24 hours symptoms / signs) or imaging evidence of infarction that is not attributable to a non-ischemic cause (i.e. not associated with infection, tumor, seizure, severe metabolic disease).
| Participants | Asundexian | Apixaban |
|---|---|---|
| Number of Participants With Ischemic Stroke | 85 | 21 |
The assessment was based on the cause-specific hazard ratio (csHR), comparing asundexian with apixaban which is based on time to first event. CV death included death due to stroke, myocardial infarction, heart failure or cardiogenic shock, sudden death or any other death due to other cardiovascular causes or CV procedures. In addition, death due to non-traumatic cardiovascular hemorrhage will be included, e.g. non-stroke intracranial hemorrhage, non-procedural or non-traumatic vascular rupture (e.g. aortic aneurysm), or hemorrhage causing cardiac tamponade
| Participants | Asundexian | Apixaban |
|---|---|---|
| Number of Participants With Cardiovascular (CV) Death | 48 | 44 |
The assessment was based on the cause-specific hazard ratio (csHR), comparing asundexian with apixaban which is based on time to first event. The diagnosis of MI requires the combination of: * Presence of acute myocardial injury (changes in cardiac biomarkers) and * Evidence of acute myocardial ischemia derived from the clinical presentation, electrocardiographic changes, or the results of myocardial or coronary artery imaging, or in case of post mortem pathological findings irrespective of biomarker values.
| Participants | Asundexian | Apixaban |
|---|---|---|
| Number of Participants With Composite of CV Death, Stroke, or Myocardial Infarction (MI) | 155 | 77 |
The assessment was based on the cause-specific hazard ratio (csHR), comparing asundexian with apixaban which is based on time to first event. Clinically relevant non-major bleeding was considered any sign or symptom of acute or sub-acute clinically overt bleeding that does not fit the criteria for the ISTH definition of major bleeding, but does meet at least one of the following criteria (based on criteria published by the EMA) (EMA 2014): * requiring medical or surgical treatment by a healthcare professional for bleeding * leading to hospitalization or increased level of care for bleeding * a change in antithrombotic therapy (including study intervention) for bleeding \*Overt bleeding required the identification of the bleeding location.
| Participants | Asundexian | Apixaban |
|---|---|---|
| Number of Participants With Composite of ISTH Major or Clinically Relevant Non-major Bleeding | 83 | 188 |
The assessment was based on the cause-specific hazard ratio (csHR), comparing asundexian with apixaban which is based on time to first event.
| Participants | Asundexian | Apixaban |
|---|---|---|
| Number of Participants With Clinically Relevant Non-major Bleeding | 67 | 140 |
The assessment was based on the cause-specific hazard ratio (csHR), comparing asundexian with apixaban which is based on time to first event. Hemorrhagic stroke was defined as an acute, atraumatic extravasation of blood into the brain parenchyma, intraventricular or subarachnoid space with associated neurological symptoms. This does not include microbleeds or hemorrhagic transformation of an ischemic stroke.
| Participants | Asundexian | Apixaban |
|---|---|---|
| Number of Participants With Hemorrhagic Stroke | 1 | 6 |
The assessment was based on the cause-specific hazard ratio (csHR), comparing asundexian with apixaban which is based on time to first event.
| Participants | Asundexian | Apixaban |
|---|---|---|
| Number of Participants With Intracranial Hemorrhage | 3 | 18 |
The assessment was based on the cause-specific hazard ratio (csHR), comparing asundexian with apixaban which is based on time to first event.
| Participants | Asundexian | Apixaban |
|---|---|---|
| Number of Participants With Fatal Bleeding | 0 | 4 |
The assessment was based on the cause-specific hazard ratio (csHR), comparing asundexian with apixaban which is based on time to first event. All other overt bleeding episodes not meeting the criteria for ISTH major or clinically relevant non-major bleeding were classified as minor bleeding (for example, bleeding from a minor wound that does not prompt a treatment for the bleeding, for instance with surgical hemostasis, or epistaxis that does not require a medical treatment for bleeding or a change in antithrombotic therapy).
| Participants | Asundexian | Apixaban |
|---|---|---|
| Number of Participants With Minor Bleeding | 187 | 317 |
The assessment was based on the cause-specific hazard ratio (csHR), comparing asundexian with apixaban which is based on time to first event.
| Participants | Asundexian | Apixaban |
|---|---|---|
| Number of Participants With Composite of Stroke, Systemic Embolism, ISTH Major Bleeding, or All-cause Mortality | 149 | 101 |
The assessment was based on the cause-specific hazard ratio (csHR), comparing asundexian with apixaban which is based on time to first event. Critical bleeding was defined as symptomatic bleeding in either of the following critical locations (intracranial, intraspinal, pericardial, intra-articular, or retroperitoneal) or as intraocular bleeding with compromised vision or intramuscular bleeding with compartment syndrome.
| Participants | Asundexian | Apixaban |
|---|---|---|
| Number of Participants With Composite of Disabling Stroke (mRS ≥ 3), Critical Bleeding, or All-cause Mortality | 51 | 56 |
Collected over Approximately 12 months. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Asundexian | 73/7,373 (1%) | 582/7,373 (7.9%) | 467/7,373 (6.3%) |
| Apixaban | 85/7,364 (1.2%) | 599/7,364 (8.1%) | 455/7,364 (6.2%) |
| Event | Asundexian | Apixaban |
|---|---|---|
| Atrial fibrillationCardiac disorders | 47/7373 | 71/7364 |
| Cardiac failureCardiac disorders | 54/7373 | 62/7364 |
| PneumoniaInfections and infestations | 22/7373 | 28/7364 |
| Acute kidney injuryRenal and urinary disorders | 26/7373 | 12/7364 |
| Cardiac failure acuteCardiac disorders | 18/7373 | 25/7364 |
| Cardiac failure chronicCardiac disorders | 18/7373 | 8/7364 |
| Cardiac failure congestiveCardiac disorders | 10/7373 | 14/7364 |
| Urinary tract infectionInfections and infestations | 7/7373 | 13/7364 |
| SyncopeNervous system disorders | 10/7373 | 12/7364 |
| Chest painGeneral disorders | 11/7373 | 11/7364 |
| Event | Asundexian | Apixaban |
|---|---|---|
| DizzinessNervous system disorders | 132/7373 | 113/7364 |
| DiarrhoeaGastrointestinal disorders | 115/7373 | 72/7364 |
| COVID-19Infections and infestations | 97/7373 | 109/7364 |
| NasopharyngitisInfections and infestations | 98/7373 | 89/7364 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 50/7373 | 96/7364 |
Full Analysis Set (FAS): All participants randomized to study intervention including participants who did not receive study intervention. N (number) =14830 Adjusted Full Analysis Set (aFAS): All participants in the Full Analysis Set excluding subjects randomized from one site in Japan. N=14810 Due to Good Clinical Practice violations, 20 participants from one site in Japan were excluded from all analyses.
| Age, Continuous(Years) | Asundexian | Apixaban | Total |
|---|---|---|---|
| Mean | 73.9 ± 7.7 | 73.9 ± 7.7 | 73.9 ± 7.7 |
| Sex: Female, Male(Participants) | Asundexian | Apixaban | Total |
|---|---|---|---|
| Female | 2656 | 2558 | 5214 |
| Male | 4759 | 4837 | 9596 |
| Ethnicity (NIH/OMB)(Participants) | Asundexian | Apixaban | Total |
|---|---|---|---|
| Hispanic or Latino | 533 | 507 | 1040 |
| Not Hispanic or Latino | 6774 | 6793 | 13567 |
| Unknown or Not Reported | 108 | 95 | 203 |
| Race (NIH/OMB)(Participants) | Asundexian | Apixaban | Total |
|---|---|---|---|
| American Indian or Alaska Native | 4 | 4 | 8 |
| Asian | 2035 | 2010 | 4045 |
| Native Hawaiian or Other Pacific Islander | 9 | 2 | 11 |
| Black or African American | 88 | 95 | 183 |
| White | 5216 | 5211 | 10427 |
| More than one race | 21 | 28 | 49 |
| Unknown or Not Reported | 42 | 45 | 87 |
Showing the first 100 of 1,069 sites across 38 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.
Ran from Dec 2022 to primary completion in Jan 2024, 13 months.
Results were first posted in Dec 2024, 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Asundexian